We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mylan (MYL) to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Mylan N.V. is scheduled to report second-quarter 2017 results on Aug 9, before the market opens. The company’s performance has been mixed so far, having topped earnings estimates in three of the trailing four quarters and in missing once. The company has delivered an average positive surprise of 1.33% in the trailing four quarters.
Last quarter, the company delivered a positive earnings surprise of 1.09%. Let’s see how things are shaping up for this announcement.
We note that shares of Mylan have gained 1.2% year to date against the industry‘s 0.4% dip.
Factors to Consider This Quarter
Concurrent with the first-quarter earnings call, Mylan stated that it expects revenues between $12.25 and $13.75 billion in 2017. The company projects earnings in the range of $5.15–$5.55 per share for 2017.
Newly launched products are likely to perform well and aid the top line, while the acquisitions of Meda and the Renaissance Topicals Business are anticipated to continue to boost the topline in the generics segment. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year for the base business in the U.S.
The biosimilars pipeline continues to progress well. The FDA Oncologic Drugs Advisory Committee (ODAC) recently unanimously recommended approval of Mylan's biosimilar version of Roche Holdings AG (RHHBY - Free Report) breast cancer drug Herceptin.
However, Mylan’s Specialty segment, of which EpiPen is the most significant product, continues to be weak. In Dec 2016, Mylan announced the launch of the authorized generic for EpiPen Auto-Injector at a wholesale acquisition cost of $300 per epinephrine injection USP two-pack, which is more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors. Sales of EpiPen Auto-Injector are anticipated to continue to decline in the current quarter as a result of increased competition and the impact of the authorized generic launch. Mylan stated that EpiPen will represent less than 5% of global revenues and less than 10% of sales in North America in 2017. Meanwhile, the company’s efforts to get Advair’s generic approved suffered a blow when the FDA issued a complete response letter to its ANDA for generic Advair Diskus.
During the earnings call, we expect investors to focus on the performance of EpiPen, newly launched drugs and progress with the biosimilars pipeline.
Our proven model does not conclusively show that Mylan is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to likely post an earnings beat. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Mylan currently carries a Zacks Rank #3. Although the rank is favorable, the company’s negative ESP makes surprise prediction difficult.
Note that, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider instead, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Impax Laboratories has an Earnings ESP of +7.14% and a Zacks Rank #3. The company is expected to release second-quarter results on Aug 9.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Mylan (MYL) to Report Q2 Earnings: What's in the Cards?
Mylan N.V. is scheduled to report second-quarter 2017 results on Aug 9, before the market opens. The company’s performance has been mixed so far, having topped earnings estimates in three of the trailing four quarters and in missing once. The company has delivered an average positive surprise of 1.33% in the trailing four quarters.
Last quarter, the company delivered a positive earnings surprise of 1.09%. Let’s see how things are shaping up for this announcement.
We note that shares of Mylan have gained 1.2% year to date against the industry‘s 0.4% dip.
Factors to Consider This Quarter
Concurrent with the first-quarter earnings call, Mylan stated that it expects revenues between $12.25 and $13.75 billion in 2017. The company projects earnings in the range of $5.15–$5.55 per share for 2017.
Newly launched products are likely to perform well and aid the top line, while the acquisitions of Meda and the Renaissance Topicals Business are anticipated to continue to boost the topline in the generics segment. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year for the base business in the U.S.
The biosimilars pipeline continues to progress well. The FDA Oncologic Drugs Advisory Committee (ODAC) recently unanimously recommended approval of Mylan's biosimilar version of Roche Holdings AG (RHHBY - Free Report) breast cancer drug Herceptin.
However, Mylan’s Specialty segment, of which EpiPen is the most significant product, continues to be weak. In Dec 2016, Mylan announced the launch of the authorized generic for EpiPen Auto-Injector at a wholesale acquisition cost of $300 per epinephrine injection USP two-pack, which is more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors. Sales of EpiPen Auto-Injector are anticipated to continue to decline in the current quarter as a result of increased competition and the impact of the authorized generic launch. Mylan stated that EpiPen will represent less than 5% of global revenues and less than 10% of sales in North America in 2017. Meanwhile, the company’s efforts to get Advair’s generic approved suffered a blow when the FDA issued a complete response letter to its ANDA for generic Advair Diskus.
During the earnings call, we expect investors to focus on the performance of EpiPen, newly launched drugs and progress with the biosimilars pipeline.
Mylan N.V. Price and EPS Surprise
Mylan N.V. Price and EPS Surprise | Mylan N.V. Quote
Earnings Whispers
Our proven model does not conclusively show that Mylan is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to likely post an earnings beat. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Mylan currently carries a Zacks Rank #3. Although the rank is favorable, the company’s negative ESP makes surprise prediction difficult.
Note that, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider instead, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Arena Pharmaceuticals, Inc. is expected to release results on Aug 7. The company has an Earnings ESP of +5.88% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Impax Laboratories has an Earnings ESP of +7.14% and a Zacks Rank #3. The company is expected to release second-quarter results on Aug 9.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>